Biological and clinical associations of c-jun activation in human breast cancer
Open Access
- 20 March 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 89 (2), 177-186
- https://doi.org/10.1002/(sici)1097-0215(20000320)89:2<177::aid-ijc13>3.0.co;2-0
Abstract
Sub‐units and regulators of the activating protein‐1(AP‐1) complex have been implicated in breast‐cancer biology, therapeutic response and prognosis. This study has immunocytochemically examined the impact of c‐jun‐protein activation on biological and clinical parameters in human primary breast cancers, employing an antibody specific for the serine 63‐phosphorylated c‐jun protein. Substantial nuclear immunostaining was commonly apparent, indicative of an activated c‐jun pool, with associations with MAP‐kinase‐signalling elements, e.g., transforming growth factor‐α (p = 0.04), epidermal growth factor receptor (p = 0.08), phosphorylated erk 1/2 MAP kinase (p = 0.001) and phosphorylated jun kinase (p = 0.05) Little association was noted with c‐fos protein, perhaps indicating alternative AP‐1 partners for c‐jun with a diversity of cellular end‐points. This may explain the lack of relationship with proliferation and grade, the imperfect association between increased c‐jun activation and poorer survival (p = 0.061), and the apparent relationship with distant metastasis (p = 0.05). While increased c‐jun activation related to poorer quality (p = 0.09) and shortened duration of endocrine response in oestrogen‐receptor‐positive patients (p = 0.018), no generalized effects on oestrogen‐regulated gene products were noted, indicating that AP‐1 influences on oestrogen‐receptor/oestrogen‐response element transactivation are unlikely to explain endocrine insensitivity. These data reinforce our belief that elevated AP‐1 signalling influences aspects of the breast‐cancer phenotype. Int. J. Cancer (Pred. Oncol.) 89:177–186, 2000.Keywords
This publication has 18 references indexed in Scilit:
- Enhanced cell motility and invasion of chicken embryo fibroblasts in response toJUN over-expressionInternational Journal of Cancer, 1999
- Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells1Endocrinology, 1998
- Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiationThe EMBO Journal, 1998
- A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate–induced invasion in mouse keratinocytesMolecular Carcinogenesis, 1997
- New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145International Journal of Cancer, 1997
- Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapyInternational Journal of Cancer, 1995
- Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivityEuropean Journal Of Cancer, 1993
- Protein kinase C-independent activation of c-jun and c-fos transcription by epidermal growth factorBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992
- Phosphorylation of c-jun mediated by MAP kinasesNature, 1991
- c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinitiesCell, 1988